Search

Displaying results 1821 - 1830 of 10000 in total
  1. Drug

    Scorpion (centruroides) immune Fab2 antivenin (equine)

    go.drugbank.com/drugs/DB13905
    Approved

    *, *C. l. tecomanus*, and *C. s. suffusus*. … This drug is a polyvalent antivenin proven to be useful against scorpion stings.

    Products: ALVENO AC 10 ML IV ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 ADET FLAKON+1 ADET ÇÖZÜCÜ AMPUL, ACSERA 5 ML ENJEKSIYONLUK COZELTI KONSANTRESI ICEREN FLAKON
  2. Drug

    Alizapride

    go.drugbank.com/drugs/DB01425
    Investigational

    This kind of pharmacological activity makes it effective for use in the treatment of various kinds of nausea and vomiting, including that which may occur postoperatively.

    Products: ALIZAPRIDA 12 MG/ML, ALIZAPRIDA 50 MG/ 2 ML
  3. Drug

    Aloe vera leaf

    go.drugbank.com/drugs/DB13906
    ApprovedInvestigational

    Aloe describes a genus including over 500 species of flowering succulent plants that grow in the Southern peninsula and various islands. … It is a perennial succulent xerophyte with elongated leaves that contain a clear gel.

    Mixtures: Re-action E, Disinfectant Wet WipesSynonyms: Lu hui ye, Lu hui (aloe vera)
  4. Target

    Transitional endoplasmic reticulum ATPase

    go.drugbank.com/bio_entities/BE0004572
    TargetHumans

    Necessary for the fragmentation of Golgi stacks during mitosis and for their reassembly after mitosis. Involved in the formation of the transitional endoplasmic reticulum (tER). The transfer of membranes from the endoplasmic reticulum to...

    Synonyms: 15S Mg(2+)-ATPase p97 subunit
  5. Drug

    Gemtuzumab ozogamicin

    go.drugbank.com/drugs/DB00056
    ApprovedInvestigational

    However, it was voluntarily withdrawn from the market in 2010 due to safety concerns, increased patient deaths and insufficient evidence of clinical benefit during confirmatory trials [L941]. … Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered

    Products: MYLOTARG 5 MG IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ, 1 FLAKON, MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/VIAL
  6. Drug

    VB-201

    go.drugbank.com/drugs/DB15259
    Investigational

    VB-201 is under investigation in clinical trial NCT01001468 (Study to Assess VB-201 in Patients With Psoriasis).

  7. Drug

    OTX-2002

    go.drugbank.com/drugs/DB17246
    Investigational

    OTX-2002 is a bicistronic messenger ribonucleic acid (mRNA) encoding for ZF-DNMT and ZF-KRAB proteins, encapsulated in a lipid nanoparticle (LNP).

  8. Drug

    EGT-201

    go.drugbank.com/drugs/DB17648
    Experimental

    EGT-201 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the alpha-N-acetyglucosaminidase (NAGLU) transgene. … Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type B.[L45939]

    Synonyms: EGT 201
  9. Drug

    NTLA-2002

    go.drugbank.com/drugs/DB17597
    Investigational

    NTLA-2002 is a lipid nanoparticle encapsulating single guide RNA (G012267) targeting the human KLKB1 gene and messenger RNA (mRNA000042) encoding Cas9. … It is an investigational therapy designed to knock out the target gene kallikrein B1 (KLKB1) to reduce plasma kallikrein activity, thereby preventing hereditary angioedema attacks.[L45738]

  10. Drug

    ETC-1001

    go.drugbank.com/drugs/DB05866
    Experimental

    ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.